Categories: News

SutheDermal.com Launches: Revolutionizing Comfort in Self-Injection Therapies

Revolutionary vibration device offers pain relief for finger pricks, GLP-1 shots, and wellness injections

BOCA RATON, Fla., April 22, 2025 /PRNewswire/ — Suthe is proud to announce the launch of its new website, SutheDermal.com, introducing DigiVibe™—a groundbreaking device designed to alleviate the discomfort and anxiety associated with self-injections and finger pricking.

With the rising prevalence of injectable treatments for conditions like diabetes, fertility protocols & weight management, SutheDermal.com addresses a critical need for a more comfortable patient experience. DigiVibe™ employs advanced vibration technology to minimize pain perception, making self-injection more manageable for users.

The newly launched website offers:

  • User-Centric Design: An intuitive interface that guides users through product information and purchasing options.
  • Educational Resources: Comprehensive guides and FAQs to assist users in understanding and utilizing DigiVibe™ effectively.
  • Secure E-Commerce Platform: A streamlined shopping experience with robust security measures to protect customer information.  

“Our mission is to enhance the quality of life for individuals requiring regular injections by providing innovative solutions that reduce discomfort and anxiety,” said Mark Lorberbaum, Founder & CEO at Suthe.

For more information, visit https://suthedermal.com.

Media Contact:
Terri Previte, Director of Digital Marketing
Mark Lorberbaum, Founder & CEO
***@suthedermal.com
(844) 503-8423

Photos:
https://www.prlog.org/13072799

Press release distributed by PRLog

View original content:https://www.prnewswire.com/news-releases/suthedermalcom-launches-revolutionizing-comfort-in-self-injection-therapies-302435113.html

SOURCE Digivibe by Suthe

Staff

Recent Posts

Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations

TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…

44 minutes ago

Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting

Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…

44 minutes ago